ACEI have been shown to have a renoprotective effect in patients with SLE [29], and current treatment guidelines support the use of renin–angiotensin–aldosterone blockade (ACEI/ARB) in these patients with LN [13]. The gene discussed is REN; the disease is lobular neoplasia.